Movement Disorders最新文献

{"title":"Aiming at the Seed: α-Synuclein Immunotherapy in Multiple System Atrophy","authors":"Akansha Jain DM, Sanjay Pandey DM","doi":"10.1002/mds.70430","DOIUrl":"10.1002/mds.70430","url":null,"abstract":"","PeriodicalId":213,"journal":{"name":"Movement Disorders","volume":"41 8","pages":"2012-2013"},"PeriodicalIF":7.7,"publicationDate":"2026-08-26","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148408046","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Qihuang Needle Therapy for Motor Symptoms in Parkinson's Disease: A Randomized Controlled Trial","authors":"Wanqing Peng MD,&nbsp;Renhui Zhao MM,&nbsp;Ziting Huang MM,&nbsp;Jingpei Zhou MD,&nbsp;Yanning Liu MM,&nbsp;Zhijuan Liu MM,&nbsp;Xinyu Li PhD,&nbsp;Jingjing Deng MM,&nbsp;Xubo Hong MM,&nbsp;Yanfang Chen MM,&nbsp;Nanbu Wang MD,&nbsp;Zhenhu Chen MD","doi":"10.1002/mds.70343","DOIUrl":"10.1002/mds.70343","url":null,"abstract":"<div>\u0000 \u0000 \u0000 <section>\u0000 \u0000 <h3> Background</h3>\u0000 \u0000 <p>Motor symptoms in Parkinson's disease (PD) often respond incompletely to medication, highlighting the need for effective adjunctive therapies. Acupuncture may offer benefits, but high-quality evidence for specialized techniques such as Qihuang needle therapy is lacking.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Objective</h3>\u0000 \u0000 <p>Our goal was to evaluate the efficacy of Qihuang needle therapy for improving motor symptoms in PD patients.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Methods</h3>\u0000 \u0000 <p>This single-center, randomized, single-blind, sham-controlled trial, enrolled 140 patients with idiopathic PD, who were assigned to either Qihuang needle therapy or sham acupuncture for nine sessions over 6 weeks, in addition to their stable medications. The primary outcome was the change in the Unified Parkinson's Disease Rating Scale Part III (UPDRS-III) score from baseline to week 6. Secondary outcomes included changes in the Non-Motor Symptoms Scale (NMSS) and the 39-item Parkinson's Disease Questionnaire (PDQ-39).</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Results</h3>\u0000 \u0000 <p>Overall, 129 participants (92.1%) completed the trial. The Qihuang needle group showed significantly greater improvement in UPDRS-III at week 6 (between-group difference: 8.45 points; 95% confidence interval [CI], 5.49–11.42; <i>P</i> &lt; 0.001), sustained at 10-week follow-up (10.88 points; 95% CI, 7.89–13.87; <i>P</i> &lt; 0.001). Significant improvements were also noted in non-motor symptoms (NMSS) and quality of life (PDQ-39) at both time points (all <i>P</i> &lt; 0.001). Greatest efficacy was observed in postural instability and gait disorder subtypes.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Conclusions</h3>\u0000 \u0000 <p>Qihuang needle therapy significantly improved motor and non-motor symptoms and quality of life in PD patients compared with that via sham acupuncture, with benefits sustained for ≥1 month. These findings support Qihuang needle therapy as a safe and effective adjunctive treatment for PD. © 2026 The Author(s). <i>Movement Disorders</i> published by Wiley Periodicals LLC on behalf of International Parkinson and Movement Disorder Society.</p>\u0000 </section>\u0000 </div>","PeriodicalId":213,"journal":{"name":"Movement Disorders","volume":"41 8","pages":"2051-2061"},"PeriodicalIF":7.7,"publicationDate":"2026-08-26","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1002/mds.70343","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147864154","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Target-Dependent Postoperative Weight Gain after Pallidothalamic Tractotomy versus Pallidotomy for Dystonia","authors":"Ryosuke Jozuka MD,&nbsp;Masahiko Nishitani MD,&nbsp;Eriko Kamijo MD,&nbsp;Kilsoo Kim MD,&nbsp;Satoru Miyao MD,&nbsp;Mika Fujiwara MD,&nbsp;Taku Nonaka MD,&nbsp;Bohui Qian MD,&nbsp;Takakazu Kawamata MD, PhD,&nbsp;Takaomi Taira MD, PhD,&nbsp;Shiro Horisawa MD","doi":"10.1002/mds.70323","DOIUrl":"10.1002/mds.70323","url":null,"abstract":"<div>\u0000 \u0000 \u0000 <section>\u0000 \u0000 <h3> Background</h3>\u0000 \u0000 <p>Postoperative weight gain is a recognized complication of deep brain stimulation, but whether ablative surgery produces target-dependent weight effects remains unknown. We investigated whether pallidothalamic tractotomy (PTT) causes greater weight gain than pallidotomy and explored spatial associations.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Methods</h3>\u0000 \u0000 <p>We retrospectively analyzed 79 patients with focal, segmental, or generalized dystonia who underwent unilateral PTT (n = 41) or globus pallidus internus (GPi) lesioning (n = 38). Multivariable linear regression quantified the effect of target on weight and body mass index (BMI) changes, adjusting for age, sex, side, preoperative BMI, follow-up duration, and Burke–Fahn–Marsden dystonia rating scale (BFMDRS) improvement. In a subset with postoperative magnetic resonance imaging (MRI), lesion overlap (N) maps and voxel-wise mean BMI-change maps were generated to explore anatomical associations.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Results</h3>\u0000 \u0000 <p>PTT resulted in greater postoperative weight gain than GPi lesioning (+6.7 ± 7.5 kg vs. +1.1 ± 4.7 kg), with ≥10 kg gain in 29.3% versus 5.3% of patients. After covariate adjustment, PTT remained independently associated with greater weight gain (adjusted difference + 5.18 kg; 95% confidence interval [CI] +13 to +8.23) and BMI increase (+1.92 kg/m²; 95% CI +0.85 to +2.99). Lesion mapping localized PTT lesions to Forel's field H1. Weight-gain hotspots mapped medial to the inferior border of the subthalamic nucleus, whereas GPi maps showed no consistent intranuclear hotspot.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Conclusions</h3>\u0000 \u0000 <p>PTT was associated with greater postoperative weight gain than pallidotomy, independent of covariates. These findings suggest that lesion target influences postoperative body-weight regulation, highlighting the potential risk of lesions extending into the caudal subthalamic region. © 2026 International Parkinson and Movement Disorder Society.</p>\u0000 </section>\u0000 </div>","PeriodicalId":213,"journal":{"name":"Movement Disorders","volume":"41 8","pages":"2062-2070"},"PeriodicalIF":7.7,"publicationDate":"2026-08-26","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147735551","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Clinical Trials in GBA1-Associated Parkinson's Disease: A Need for Molecular Classification","authors":"Ziv Gan-Or MD, PhD","doi":"10.1002/mds.70328","DOIUrl":"10.1002/mds.70328","url":null,"abstract":"","PeriodicalId":213,"journal":{"name":"Movement Disorders","volume":"41 8","pages":"2002-2006"},"PeriodicalIF":7.7,"publicationDate":"2026-08-26","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147667025","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"The Place of Adaptive Deep Brain Stimulation in Parkinson's Disease: Spatial before Temporal Optimization","authors":"Wesley Thevathasan MBBS, FRACP, DPhil,&nbsp;Matthew Petoe BSc, BEng, PhD","doi":"10.1002/mds.70368","DOIUrl":"10.1002/mds.70368","url":null,"abstract":"","PeriodicalId":213,"journal":{"name":"Movement Disorders","volume":"41 8","pages":"1921-1923"},"PeriodicalIF":7.7,"publicationDate":"2026-08-26","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148039202","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Physical Activity and Exercise for People with Parkinson's Disease: The Past, Present, and Future","authors":"Daniel M. Corcos BEd, MS, MA, PhD,&nbsp;Miranda J. Munoz PhD,&nbsp;Niyati Mehta BA,&nbsp;Kathleen E. McKee MD, MPH","doi":"10.1002/mds.70396","DOIUrl":"10.1002/mds.70396","url":null,"abstract":"<p>This invited perspective paper celebrating the 40th anniversary of <i>Movement Disorders</i> demonstrates that the topic of physical activity and exercise as a treatment for Parkinson's disease did not feature before 2002 in this journal. The topic of physical activity and exercise garnered increasing recognition over the next two decades with several important papers published in <i>Movement Disorders</i>. As of 2026, there are four well-recognized treatments for Parkinson's disease: (1) exercise and physical activity; (2) general lifestyle modifications, including avoiding harmful environmental toxins; (3) medication; and (4) surgery and devices. The paper concludes by suggesting a variety of questions, the answers to which will improve clinicians' ability to help patients understand and implement the full Parkinson's exercise prescription. © 2026 The Author(s). <i>Movement Disorders</i> published by Wiley Periodicals LLC on behalf of International Parkinson and Movement Disorder Society.</p>","PeriodicalId":213,"journal":{"name":"Movement Disorders","volume":"41 8","pages":"2014-2021"},"PeriodicalIF":7.7,"publicationDate":"2026-08-26","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1002/mds.70396","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148255529","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Addressing Care Partner Burden from the Underrecognition of Iatrogenic Sexual Behavior Changes in Parkinson's Disease","authors":"Laura Silveira-Moriyama MD, PhD,&nbsp;Michiko K. Bruno MD,&nbsp;Susanne A. Schneider MD, PhD,&nbsp;Christos Ganos MD,&nbsp;Laura Williams MRCPI, MD,&nbsp;Renato P. Munhoz MD, PhD,&nbsp;Tamara Pringsheim MD, MSc,&nbsp;Roy N. Alcalay MD,&nbsp;Indu Subramanian MD,&nbsp;Anthony E. Lang MD, FRCPC","doi":"10.1002/mds.70315","DOIUrl":"10.1002/mds.70315","url":null,"abstract":"","PeriodicalId":213,"journal":{"name":"Movement Disorders","volume":"41 8","pages":"1993-2001"},"PeriodicalIF":7.7,"publicationDate":"2026-08-26","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147871370","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Phase 2a Randomized Controlled Trial of TPN ‐101, A Nucleoside Reverse Transcriptase Inhibitor, in Progressive Supranuclear Palsy","authors":"Andrew Satlin, Michael G. Cordingley, Debra K. Liebert, Walter Bee, Ethan G. Geier, John M. Sedivy, Jay Soto, Jianmin Duan, Samuel P. Dickson, Leslie Chu, Eckard Weber","doi":"10.1002/mds.70470","DOIUrl":"https://doi.org/10.1002/mds.70470","url":null,"abstract":"Background Preclinical and human brain postmortem studies indicate that progressive supranuclear palsy (PSP) is associated with increased expression of the retrotransposon Long Interspersed Nuclear Element‐1 (L1Hs). L1Hs activity initiates an innate immune response that leads to neuroinflammation and neurodegeneration, which can be attenuated by inhibiting the L1Hs‐encoded reverse transcriptase. TPN‐101 is a potent inhibitor of the L1Hs reverse transcriptase. Objective The objective of this study was to assess the safety, pharmacokinetics, and biomarker and clinical effects of TPN‐101 in patients with PSP. Methods A double‐blind, placebo‐controlled, parallel‐group study randomly assigned patients with probable PSP to receive TPN‐101 100, 200, or 400 mg, or placebo daily for 24 weeks. Following the double‐blind period, all patients received open‐label TPN‐101 400 mg daily for 24 weeks. The primary outcome was the incidence and severity of treatment‐emergent adverse events. Biomarker, clinical, and TPN‐101 pharmacokinetic assessments were conducted throughout the study. Results Forty‐two patients were randomly assigned to TPN‐101 100 mg (N = 11), 200 mg (N = 10), 400 mg (N = 11), or placebo (N = 10). TPN‐101 was well tolerated, with no notable safety differences between any drug dose and placebo. Greater reductions in cerebrospinal fluid levels of neurofilament light chain with increasing dose were seen in patients taking TPN‐101 during the double‐blind period, compared with an increase in the placebo arm. There were no differences among the treatments on the Progressive Supranuclear Palsy Rating Scale during the double‐blind period. Conclusions The safety, pharmacokinetics, and reductions in biomarkers of neuroinflammation and neurodegeneration warrant future trials powered to detect clinical effects of TPN‐101 in PSP. © 2026 International Parkinson and Movement Disorder Society.","PeriodicalId":213,"journal":{"name":"Movement Disorders","volume":"159 1","pages":""},"PeriodicalIF":8.6,"publicationDate":"2026-08-21","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148768691","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Pathogenic GBA1 Variants and their Interaction with the Gut–Microbiota–Brain Axis in Parkinson's Disease","authors":"Helen Dainton‐Howard, Phillip Engen, Kristi Lawrence, Maliha Shaikh, Mohamad Abdel‐Mohsen, Stefan Green, Ankur Naqib, Neha Joshi, Michelle Villanueva, Alana Kirby, Ali Keshavarzian, Christopher Goetz","doi":"10.1002/mds.70496","DOIUrl":"https://doi.org/10.1002/mds.70496","url":null,"abstract":"","PeriodicalId":213,"journal":{"name":"Movement Disorders","volume":"97 1","pages":""},"PeriodicalIF":8.6,"publicationDate":"2026-08-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148768692","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Alternative Translation in PRKN : Implications for Precision Medicine","authors":"Léo Coutinho, Hélio A.G. Teive","doi":"10.1002/mds.70511","DOIUrl":"https://doi.org/10.1002/mds.70511","url":null,"abstract":"","PeriodicalId":213,"journal":{"name":"Movement Disorders","volume":"16 1","pages":""},"PeriodicalIF":8.6,"publicationDate":"2026-08-18","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148754378","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}